Ratings Surperformance

Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-

Ratings ESG MSCI

Ratings Protalix BioTherapeutics, Inc.: Strengths and Weaknesses

  • Overall, and from a short-term perspective, the company presents an interesting fundamental situation.
Highlights: Protalix BioTherapeutics, Inc.
  • Growth remains a strong point in this company. In their sales forecast, analysts sound optimistic with regard to sales prospects.
  • For the past twelve months, EPS forecast has been revised upwards.
  • Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
  • The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
  • Over the past twelve months, analysts' opinions have been strongly revised upwards.
Weaknesses: Protalix BioTherapeutics, Inc.
  • The company's currently anticipated earnings per share (EPS) growth for the next few years is a notable weakness.
  • The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 11.5 times its estimated earnings per share for the ongoing year.

Rating Financials

Protalix BioTherapeutics, Inc. SectorIsrael

Fundamentals

-

Growth

Revenue growth

EPS growth

FCF growth

-

Profitability

EBITDA Margin

-

EBIT Margin

Net Margin

Capital Efficiency

-

ROA

-

ROCE

-

ROE

-

Financial Health

-

Gearing

-

Leverage

-

Capital Intensity

-

Balance sheet growth

-

Long Term balance sheet growth

-

Long term revenue growth

Long term EPS growth

More ratings

Rating Valuation

Protalix BioTherapeutics, Inc. SectorIsrael

Global Valuation

-

Enterprise Value

-

EV/Revenue

-

EV/EBITDA

-

EV/FCF

-

Equity Valuation

-

P/E

PBR

-

Dividend Yield

-

EV/EBIT

-

CAPEX/Revenue

-
More ratings

Rating Consensus

Protalix BioTherapeutics, Inc. SectorIsrael

Consensus

Analysts' buy/sell recommendations

Analysts' recommendations evolution (1 year)

Analysts' recommendations evolution (4 months)

Analysts' target price

Analysts' target price evolution (1 year)

Analysts' target price evolution (4 months)

Analysts' recommendations evolution (7 days)

Target Price evolution (7 days)

More ratings

Rating Business Predictability

Protalix BioTherapeutics, Inc. SectorIsrael

Visibility

Analysts' coverage

Financial estimates divergence

-

Analysts' recommendations divergence

Analysts' Target price divergence

Surprise rates

Rating Revisions

Protalix BioTherapeutics, Inc. SectorIsrael

Financial revisions

Revenue revisions (1 year)

Revenue revisions (4 months)

EPS revisions (1 year)

EPS revisions (4 months)

EPS revisions (7 days)

Revenue revisions (7 days)

More ratings


Capi.($) Investor ESG MSCI Fundamentals Financial revisions Global Valuation Visibility Consensus
222M - - - -
1,031B
A
638B
BBB
462B
AAA
-
359B
A
335B
AA
273B
AAA
253B
A
228B
A
185B
AA
Average 376.41B
AA
Weighted average by Cap.
AA
  1. Stock Market
  2. Stocks
  3. PLX Stock
  4. PLX Stock
  5. Ratings Protalix BioTherapeutics, Inc.